Contact UsInvestorsCareersMediaScienceContact Us
HomeMedia Centre

Media Centre

National Campaign Encourages Canadians to go “Out of Office” This Migraine Awareness Month
Pfizer invests $4.9M in McMaster University study to help improve care for multiple myeloma patients in Canada
Pfizer Announces Availability of ABRYSVOTM in Canada for Immunization of Pregnant Individuals and Adults 60+
VELSIPITY™ Receives Health Canada Approval for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
Pfizer Canada and McMaster University to foster health equity in vaccine science
NURTEC ODT® is Now Available in Canada for the Treatment of Acute Migraine
Pfizer Canada named one of Montreal’s Top Employers for 2024
Crohn’s and Colitis Canada and Pfizer Canada Introduce the 2024 Diversity, Equity and Inclusion Awards Program in IBD Research
ELREXFIO™ is authorized by Health Canada for adults with relapsed or refractory multiple myeloma in Canada
Sumitomo Pharma and Pfizer Canada Announce Availability of MYFEMBREE® in Canada
Pfizer Canada named one of Canada’s Top Employers for Young People for 2024
Health Canada Approves Pfizer’s Bivalent Respiratory Syncytial Virus (RSV) Vaccine for Older Adults and Infants Through Maternal Immunization
03.01.24Health Canada approves Pfizer Canada’s gene therapy
in hemophilia B
04.12.23LITFULO™ Receives Health Canada Approval, Becoming the First Approved Treatment for Severe Alopecia Areata in Canada27.11.23Pfizer Canada, Colorectal Cancer Canada and Thermo Fisher Scientific announce recipients of colorectal cancer grant15.11.23Pfizer and BioNTech Receive Prestigious Prix Galien Canada Innovative Product Award for COMIRNATY, Canada’s First Approved COVID-19 Vaccine06.11.23Crohn’s and Colitis Canada and Pfizer Canada Announce 2023 Women in IBD Award Recipients02.11.23The Lung Health Foundation, Lung Cancer Canada, the Quebec Lung Association and Pfizer Canada announce recipients of the 2023 national Quality Improvement grant program to support Canadians living with lung cancer23.10.23Pfizer Canada and the Skin Spectrum Summit reveal recipients of new scholarship to improve dermatological care for racialized Canadians19.10.23Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE®16.10.23Pfizer Canada Invests in Canadian Innovation, Announcing Winners of Open Call for Healthcare Solutions28.09.23
Pfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
31.07.23Rethink Breast Cancer and Pfizer Canada announce recipients of the 2023 national quality improvement grants to support metastatic breast cancer patients17.07.23Pfizer Canada and the Skin Spectrum Summit announce a new scholarship to improve dermatological care for racialized Canadians06.06.23Pfizer Canada and the Canadian Cardiovascular Society announce recipients of research fellowship awards focused on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)17.05.23Pfizer Canada Launches National Initiative to Propel Startup Solutions for Key Challenges in Healthcare14.04.23Pfizer Canada Initiates Submission to Health Canada for Its Bivalent Respiratory Syncytial Virus (RSV) Vaccine08.03.23Women in Governance Awards Gold Level Gender Parity Certification to Pfizer Canada  03.02.23National Advisory Committee on Immunization NACI) provides strong recommendation for PREVNAR 20 09.12.22Pfizer and BioNTech's Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age07.11.22Crohn's and Colitis Canada and Pfizer Canada Announce 2022 Women in IBD Award Recipients03.11.22Canadian Paralympic Committee and Pfizer Canada renew long-time commitment to growing Paralympic Movement through 202518.10.22Together with Bladder Cancer Canada, EMD Serono and Pfizer Canada announce inaugural recipients of national quality improvement grants......07.10.22Pfizer and BioNTech's Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine ......09.09.22COMIRNATY, Pfizer-BioNTech COVID-19 Vaccine, Receives Health......25.07.22Pfizer Canada and BioNTech initiate rolling...21.07.22Pfizer announces PREVNAR 20™ (pneumococcal 20-...11.07.22Pfizer Canada and Rethink Breast Cancer announce...04.07.22Health Canada Approves the Use of CIBINQO (...23.06.22Pfizer Canada and BioNTech initiate rolling...07.06.22Pfizer welcomes the Quebec government for its new...16.05.22Najah Sampson Is Appointed President of Pfizer...29.04.22Pfizer Canada Achieves Women in Governance Parity...25.04.22Pfizer Canada Remarks on Vaccine Equity to the...08.03.22Pfizer Canada named one of Canada’s Best...28.02.22Pfizer’s Biosimilar ABRILADA™ (adalimumab) for...18.02.22Pfizer Canada Named Top Family-Friendly Employer...18.01.22Pfizer Canada named one of Canada’s Top Employers...17.01.22Pfizer Receives Health Canada Authorization for...03.12.21Pfizer to Provide Canada with 1 Million Courses...01.12.21PFIZER CANADA INITIATES SUBMISSION TO HEALTH...19.11.21PFIZER AND BIONTECH RECEIVE HEALTH CANADA...12.11.21Pfizer Canada recognized as one of Canada’s Top...09.11.21Crohn’s and Colitis Canada and Pfizer Canada...09.11.21Pfizer and BioNTech Achieve Health Canada...28.10.21HEALTH CANADA APPROVES NGENLA (SOMATROGON)...18.10.21Pfizer Canada and BioNTech Initiate Submission to...16.09.21PFIZER-BIONTECH COVID-19 VACCINE COMIRNATY...13.09.21Pfizer enters a new collaboration in...26.07.21PFIZER CANADA AND RETHINK BREAST CANCER ANNOUNCE...15.07.21HEALTH CANADA APPROVES THE USE OF EUCRISA IN...07.06.21Health Canada Expands Approval of Pfizer’s...05.05.21PFIZER AND BIONTECH RECEIVE HEALTH CANADA...29.04.21BAVENCIO RECEIVES REIMBURSEMENT RECOMMENDATION...23.04.21PFIZER REACHES AGREEMENT WITH CANADA TO SUPPLY UP...16.04.21STATEMENT: PFIZER TO SUPPLY ADDITIONAL EIGHT...31.03.21HEALTH CANADA APPROVES BRAFTOVI (ENCORAFENIB) IN...02.03.21HEALTH CANADA APPROVES BRAFTOVI AND MEKTOVI FOR...23.03.21Statement: Pfizer position on dosing intervals of...11.03.21Pfizer Canada announces the launch of a joint...08.03.21Remarks by Pfizer Canada President Cole Pinnow to...09.02.21Pfizer-BioNTech COVID-19 Vaccine Canadian Label...09.02.21Pfizer Canada Recognized as an Employee-...22.01.21HEALTH CANADA APPROVES BAVENCIO® FOR THE...19.01.21UPDATE ON SUPPLY OF THE PFIZER-BIONTECH COVID-19...18.12.20UPDATE – Pfizer Canada Responds to COVID-1909.12.20Pfizer and BioNTech Achieve Health Canada...04.12.20Pfizer Canada donation will help new researchers...16.11.20Pfizer Completes Transaction to Combine Its...06.11.20Crohn’s and Colitis Canada and Pfizer Canada are...09.10.20Pfizer Canada and BioNTech Initiate Rolling...05.08.20Pfizer and BioNTech to supply Canada with their...31.07.20APPROVAL OF EXPANDED INDICATION FOR PrGENOTROPIN...18.06.20CQDM grants $1.15 M in funding to Professor Yves...17.06.20Assiniboine and Pfizer Canada partner to expand...12.06.20HEALTH CANADA APPROVAL OF DAURISMO® (GLASDEGIB)21.05.20Crohn’s and Colitis Canada and Pfizer Canada...01.05.20Pfizer Canada Update - Supply of Essential...13.03.20STATEMENT – Pfizer Canada COVID-19 Direction to...06.02.20HEALTH CANADA APPROVAL OF MYLOTARG® (GEMTUZUMAB...31.01.20Pfizer Canada is recognized as one of Montréal’s...22.01.20Cole Pinnow Is Appointed President of Pfizer...

If you are a member of the media with specific questions about our Canadian operations, please call 1-866-9Pfizer (1 866 973-4937) or email [email protected] to reach a member of the Pfizer Canada Corporate Affairs team. To stay up to date on Pfizer Canada news, follow us on social media:

About UsOur ProductsHelping Communities Our Voice Suppliers Distribution ChannelPfizer WorldwideMedia CentreTerms Of Use Careers Healthcare ProfessionalsContact UsPrivacy PolicyCopyright © Pfizer Canada 2022 All rights reserved. The information is intended only for residents of Canada. ® Pfizer Inc, used under license